0.10Open0.10Pre Close50 Volume165 Open Interest5.00Strike Price500.00Turnover339.51%IV191.43%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1818Delta0.1886Gamma17.50Leverage Ratio-0.0091Theta0.0001Rho3.18Eff Leverage0.0011Vega
NRX Pharmaceuticals Stock Discussion
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of
https://www.moomoo.com/t/news/post/42897644/mbyzFRmrUf
Benzinga· 1 min ago
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has announced potential acquisition and financing agreements for $30 million in currently-operating interventional psychiatry clinics. Key points include:
1. A $30 million Term Sheet from a qualifi...
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals (NASDAQ:NRXP) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Secured $10.8-$16.3 million in convertible-debt funding to support FDA New Drug Applications for NRX-100(ketamine) and NRX-101.
2. Plans to file NDAs for NRX-100 in suicidal depression and NRX-101 for Acceler...
Set ready
No comment yet